Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

which reported in March 2024 that—in a trial of more than 3,500 people with type 2 diabetes—Ozempic lowered the risk of kidney disease progression and death from kidney or cardiovascular ...

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with chronic kidney disease.

A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name ...

Ozempic becomes the first GLP-1 treatment option for people with type 2 diabetes and chronic kidney disease Mario Tama ... was made following a clinical trial of more than 3,500 people where ...

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

about a third of adults with diabetes also have chronic kidney disease, according to the U.S. Centers for Disease Control and Prevention. The clinical trial tested the efficacy of Ozempic when ...